NPCA peer-reviewed Publications

The NPCA are involved in the ongoing publication of high-quality peer-reviewed articles. New publications will be announced via this website and Twitter.

Dodkins J, Cook A, Mayne E, Parry MA, Nossiter J, Payne H, Cowling TE, Tree A, Aggarwal A, Clarke N, van der Meulen J. Geographic, socioeconomic and demographic inequalities in the incidence of metastatic prostate cancer at time of diagnosis in England: a population-based evaluation. BMJ Oncology 2025: April 1

Dodkins J, Cook A, Mayne E, Parry MA, Parry MG, Boyle J, Nossiter J, Cowling TE, Tree A, Clarke N, van der Meulen J, Aggarwal A. Are Evidence-Based Guidelines Translating into Clinical Practice? A National Population-Based Study of the Use of Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in England. European Journal of Cancer 2025: March 2

Dodkins J, Zachou G, Rashid A, van der Meulen J, Nossiter J, Tree A, Aggarwal A. Improving performance in radiation oncology: An international systematic review of quality improvement interventions. Radiotherapy and Oncology 2025: May

Dodkins J, Cook A, Morris M, Nossiter J, Prust S, Waller S, van der Meulen J, Aggarwal A, Clarke N, Payne H. Organisation and delivery of supportive services for patients with prostate cancer in the National Health Service in England and Wales: a national cross-sectional hospital survey and latent class analysis. BMJ Open 2023: Nov 22

Parry M, Sujenthiran A, Nossiter J, Morris M, Berry B, Nathan A, Aggarwal A, Payne H, van der Meulen J, Clarke N. Prostate cancer outcomes following whole-gland and focal high-intensity focused ultrasound. BJU Int. 2023: Jul 25

Dodkins J, Nossiter J, Cook A, Payne H, Clarke N, van der Meulen J, Aggarwal A. Does Research from Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer Treatment Translate into Access to Treatments for Patients in the “Real World”? A Systematic Review. European Urology Oncology. 2023: June 27

Dodkins J, Morris M, Nossiter J, van der Meulen J, Payne H, Clarke N, Aggarwal A. Practicalities, challenges and solutions to delivering a national organisational survey of cancer service and processes: Lessons from the National Prostate Cancer Audit. Journal of Cancer Policy. 2022: June 24

Sujenthiran A, Parry M, Dodkins J, Nossiter J, Morris M, Berry B, Nathan A, Cathcart P, Clarke N, Payne H, van der Meulen J, Aggarwal A. Treatment-related toxicity using prostate bed versus prostate bed and pelvic lymph node radiation therapy following radical prostatectomy: A national population-based study. Clin Transl Radiat Oncol. 2023: Apr 11

Nathan A, Morris M, Parry MG, Berry B, Sujenthiran A, Nossiter J, Payne H, van Der Meulen J, Clarke NW, Green JS. Interventions for obstructive uropathy in advanced prostate cancer: a population-based study.  BJU international. 2022: November

Fankhauser CD, Parry MG, Ali A, Cowling TE, Nossiter J, Sujenthiran A, Berry B, Morris M, Aggarwal A, Payne H, van der Meulen J. A low prostate specific antigen predicts a worse outcome in high but not in low/intermediate-grade prostate cancer.  European Journal of Cancer. 2022

Nossiter J, Morris M, Parry M, Sujenthiran A, Cathcart P, van der Meulen J, Aggarwal A , Payne H, Clark N. Impact of COVID-19 on the diagnosis and treatment of men with prostate cancer. BJU international. 2022: January 25

Parry M, Nossiter J, Morris M , Sujenthiran A, Skolarus T, Berry B, Nathan A, Cathcart P , Aggarwal A , van der Meulen J, Trinh Q-D , Payne H, Clark N. Comparison of the treatment of men with prostate cancer between the US and England: An international population-based study. Prostate Cancer and Prostatic Diseases. 2022: January 10.

Parry MG, Skolarus TA, Nossiter J, Sujenthiran A, Morris M, Cowling TE, Berry B, Aggarwal A, Payne H, Cathcart P, Clarke NW, van der Meulen J. Urinary incontinence and the utilisation of incontinence surgery after radical prostatectomy: Patient-reported outcomes from a nationwide population-based study. BJU international. 2021: November 30

Nossiter J, Morris M, Cowling TE, Parry MG, Sujenthiran A, Aggarwal A, Payne H, van der Meulen J, Clarke NW and Cathcart PJ. Hospital volume and outcomes after radical prostatectomy: a national population-based study using patient-reported urinary continence and sexual function. Prostate Cancer and Prostatic Diseases. 2021: September 08.

Parry MG, Boyle J, Nossiter J, Morris M, Sujenthiran A, Berry B, Cathcart PJ, Aggarwal A, van der Meulen J, Payne H and Clarke NW. Determinants of variation in radical local treatment for men with high-risk localised or locally advanced prostate cancer in England. Prostate Cancer and Prostatic Diseases. 2021: September 07.

Aggarwal A, Nossiter J, Parry M, Sujenthiran A, Cathcart P, Clarke NW, Payne H, van der Meulen J.Public reporting of outcomes in radiation oncology: The National Prostate Cancer Audit. Lancet Oncology. 2021: March 04

Aning J, Parry  MG, van der Meulen J, Fowler  S, Payne  S, McGrath J, Challacombe B, Clarke NW. How reliable are surgeon-reported data? A comparison of the British Association of Urological Surgeons radical prostatectomy audit with the National Prostate Cancer Audit Hospital Episode Statistics-linked database. BJU international. 2021: March 21

Parry MG, Nossiter J, Sujenthiran A, Cowling TE, Patel RN, Morris M, Berry B, Cathcart PJ, Clarke NW, Payne H, van der Meulen J and Aggarwal A. Impact of High-Dose-Rate and Low-Dose-Rate Brachytherapy Boost on Toxicity, Functional and Cancer Outcomes in Patients Receiving External Beam Radiation Therapy for Prostate Cancer: A National Population-Based Study. International Journal of Radiation Oncology* Biology* Physics. 2021; 109 (5):1219-1229.

Parry MG, Nossiter J, Cowling TE, Sujenthiran A, Berry B, Cathcart PJ, Clarke NW, Payne H, van der Meulen J and Aggarwal A. Patient-reported functional outcomes following external beam radiation therapy for prostate cancer with and without a high-dose rate brachytherapy boost: A national population-based study. Radiotherapy and Oncology. 2021; 155: 48-55.

Parry MG, Nossiter J, Cowling TE, Sujenthiran A, Berry B, Cathcart PJ, Clarke NW, Payne H and van der Meulen J, Aggarwal A. Toxicity of pelvic lymph node irradiation with intensity modulated radiation therapy for high-risk and locally advanced prostate cancer: a national population-based study using patient-reported outcomes. International Journal of Radiation Oncology* Biology* Physics. 2020; 108 (5):1196-1203.

Parry MG, Cowling TE, Sujenthiran A, Nossiter J, Berry B, Cathcart PJ, Aggarwal A, Payne H, van der Meulen J, Clarke NW and Gnanapragasam VJ. Risk stratification for prostate cancer management: value of the Cambridge Prognostic Group classification for assessing treatment allocation. BMC Medicine. 2020; 18(1):1-9.

Berry B, Parry MG, Sujenthiran A, Nossiter J, Cowling TE, Aggarwal A, Cathcart PJ, Payne H, van der Meulen J, Clarke NW. Comparison of complications after transrectal and transperineal prostate biopsy: a national population-based study. BJU international. 2020; 126(1):97-103.

Nossiter J, Sujenthiran A, Cowling TE, Parry MG, Charman SC, Cathcart PJ, Clarke NW, Payne H, van der Meulen J, Aggarwal A. Patient-Reported Functional Outcomes After Hypofractionated or Conventionally Fractionated Radiation for Prostate Cancer: A National Cohort Study in England. J Clin Oncol. 2020; 38(7):744-752.

Sujenthiran A, Parry MG, Nossiter J, Berry B, Cathcart PJ, Clarke NW, Payne H, van der Meulen J, Aggarwal A. Comparison of treatment-related toxicity with hypofractionated or conventionally fractionated radiation therapy for prostate cancer: a national population-based study. Clinical Oncology. 2020; 32(8):501-508.

Parry MG, Sujenthiran A, Cowling TE, Nossiter J, Berry B, Cathcart PJ, Clarke, NW, Payne H, Aggarwal A and van der Meulen J. Identifying skeletal-related events for prostate cancer patients in routinely collected hospital data. Cancer Epidemiology. 2019; 63: 101628.

Parry MG, Sujenthiran A, Cowling TE, Nossiter, J, Cathcart PJ, Clarke NW, Payne H, van der Meulen J and Aggarwal A. Treatment-Related Toxicity Using Prostate-Only Versus Prostate and Pelvic Lymph Node Intensity-Modulated Radiation Therapy: A National Population-Based Study. J Clin Oncol. 2019; 37(21):1828-1835

Parry MG, Sujenthiran A, Cowling TE, Nossiter J, Cathcart PJ, Clarke NW, Payne H, Aggarwal A, van der Meulen J. Impact of cancer service centralisation on the radical treatment of men with high-risk and locally advanced prostate cancer: A national cross-sectional analysis in England. Int J Cancer. 2019; 145(1):40-48.

Parry MG, Sujenthiran A, Cowling TE, Charman SC, Nossiter J, Aggarwal A, Clarke NW, Payne H and van der Meulen J. Imputation of missing prostate cancer stage in English cancer registry data based on clinical assumptions. Cancer Epidemiol. 2019; 58:44-51.

Nossiter J, Sujenthiran A, Charman SC, Cathcart PJ, Aggarwal, A, Payne, H, Clarke, NW and van der Meulen, J. Robot-assisted radical prostatectomy vs laparoscopic and open retropubic radical prostatectomy: functional outcomes 18 months after diagnosis from a national cohort study in England. British Journal of Cancer. 2018; 118(4):489-494.

Sujenthiran A, Nossiter J, Parry MG, Charman SC, Cathcart PJ, van der Meulen J, Clarke NW, Payne H and Aggarwal A. Treatment-related toxicity in men who received Intensity-modulated versus 3D-conformal radiotherapy after radical prostatectomy: A national population-based study. Radiotherapy and Oncology. 2018; 128(2):357-363.

Sujenthiran A, Nossiter J, Parry, MG, Charman SC, Aggarwal A, Payne H, Dasgupta P, Clarke NW, van der Meulen J and Cathcart PJ. National cohort study comparing severe medium-term urinary complications following radical prostatectomy: robot-assisted versus laparoscopic versus retropubic open radical prostatectomy. BJU international. 2017; 121(3):445-452.

Sujenthiran A, Nossiter J, Charman SC, Parry MG, Dasgupta P, van der Meulen J, Cathcart PJ, Clarke NW, Payne H and Aggarwal A. National population-based study comparing treatment-related toxicity in men who received intensity modulated versus 3-dimensional conformal radical radiation therapy for prostate cancer. International Journal of Radiation Oncology* Biology* Physics. 2017; 99(5): 1253-1260.

Sujenthiran A, Charman SC, Parry M, Nossiter J, Aggarwal A, Dasgupta P, Payne H, Clarke NW, Cathcart P and van der Meulen J. Quantifying severe urinary complications after radical prostatectomy: the development and validation of a surgical performance indicator using hospital administrative data. BJU international. 2017; 120(2): 219-225.

Aggarwal A, Nossiter J, Cathcart PJ, Rashbass J, Payne H and van der Meulen J. The National Prostate Cancer Audit–results from the organisational survey of NHS Trusts in England. Clinical Oncology. 2017; 27(3): 482-9.

Aggarwal A, Cathcart PJ, Payne H, Neal DE, Rashbass J, Nossiter J and van der Meulen J. The National Prostate Cancer Audit—introducing a new generation of cancer audit. Clinical Oncology. 2017; 26(2):90-3.

Cathcart P, Nossiter J, Aggarwal A, Rashbass J, Lyratzopoulos Y, Payne H, Neal DE and van der Meulen J. The first national clinical audit of prostate cancer care. BJU international. 2013;112(7):883-4.